Bionaturis announces H1-2017 and YTD results

Executive Summary

Reports Revenue YTD of €1.28 million, expecting more than 60% growth for the full year 2017
Reports EBITDA YTD of €355 k, +802 thousand euros compared to the full year 2016
Reports the executions of an exclusive license agreement for the development, registration, manufacturing, and commercialization of BNT005 in Argentina and Paraguay.
Reports the signing of an Evaluation and Licensing agreement with exclusive worldwide license rights (except in Argentina and Paraguay) for the development, registration and commercialization of BNT005 with a top leading company in the sector
Reports ZIP patents granted in USA, EUROPE and JAPAN
Reports reaching an E&O agreement with a global leader for the exclusive development, registration and marketing of a probiotic for oral application, indicated to improve oral health in companion animals
Reports the signing by Biobide of new relevant contracts with three leading companies in the agrochemical and biomedicine sectors, for a cumulative amount worth of USD 1.39 million
Reports BNT005 patent granted in CHINA.


Click here to see the official document. (only spanish)


October 27th, 2017|Blog english|Comments Off on Bionaturis announces H1-2017 and YTD results

Bionaturis Group increases recurring sales 21.7%, keeping a CAGR of 24.1% on net sales between 2012 and 2015

Bionaturis Group has released FY2015 audited results showing a continuous growth in many of its main performance indicators at organic level. Thus, the recurring business coming from the CRO and consumer products divisions has grown 21.7% YOY, meaning a CAGR of 24.1% on net sales for the whole group between 2012-15. Regarding the human and animal health division -which business model requires a more focused analysis on the richness and quality of the pipeline- the Group announced the addition of up to six new programs, five of which are targeted specifically to highly lucrative niche markets within animal health, positioning the group as a partner of choice for cutting-edge developments in this sector.

From the angle of an effective presence in other international markets the Group signed an outstanding agreement with the Administrative Committee of the high technology Industrial development zone of Changshu City (Jiangsu, China), which shall support the start up phase of the subsidiary BNT China Biosciences. Also during 2015 the subsidiary BBD Biophenix USA was created, generating an immediate effect on the increase of contracts with U.S. entities, such as the one signed with the NIH (National Institute of Health), a leading global institution in the health sector.

For further details, click here

April 30th, 2016|Blog english, Hechos Relevantes|Comments Off on Bionaturis Group increases recurring sales 21.7%, keeping a CAGR of 24.1% on net sales between 2012 and 2015

Bionaturis signs a strategic agreement for its corporate expansion in China

As part of the agreement, Bionaturis Group will establish its first subsidiary company in China in the new technological area of Changshu (Jiangsu).

The new technological and industrial area of Changshu has been the one which has relied most on hosting the Spanish biotechnological group.

Bionaturis’ system for the development of biological medicinal products, known as Flylife, will serve as a baseline for the project.

Jerez de la Frontera, July 2nd 2015. Bionaturis Group and the Administrative Committee of Changshu New & Hi-Tech Industrial Development Zone –CNZ- (Jiangsu) – have signed a strategic agreement to host a subsidiary company of the biotechnological Spanish group, which will serve to develop and allocate biotechnological products in the Asian market.

As part of the agreement, within the park Bionaturis Group will have cutting-edge facilities in order to carry out its activities, as well as a diversity of direct incentive programs. In a first phase, facilities of 600 meters squared have been set out, which include a laboratory area and an administrative one. The laboratory area will host, among other services, Bionaturis’ biological medical production system, known as Flylife, and its capacity to develop state-of-the-art vaccines for human and animal health. In the new subsidiary company, the Spanish Group will also have a development department as well as a commercial office.

Currently, Bionaturis Group develops, at different stages, a variety of medicines intended for human health, as well as veterinary products that act or prevent habitual diseases in livestock (poultry, pigs, cattle…), farmed fish and pet animals.

Victor Infante, Chief Executive of Bionaturis Group, believes that “China is and will increasingly be one of the main markets in human and animal health. The commitment of Changshu’s authorities to host Bionaturis Group is a proof of […]

July 2nd, 2015|Blog english, Press Releases|Comments Off on Bionaturis signs a strategic agreement for its corporate expansion in China

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.